Enterohaemorrhagic Escherichia coli haemolysin is cleaved and inactivated by serine protease EspPα

The haemolysin from enterohaemorrhagic Escherichia coli (EHEC-Hly) and the serine protease EspPα are putative virulence factors of EHEC. We investigated the interplay between these secreted factors and demonstrate that EspPα cleaves the 107 kDa large EHEC-Hly. Degradation was observed when purified EspPα was added to a growing culture of an EHEC-Hly-expressing strain, with isolated proteins and with coexpressing strains, and was independent of the EHEC serotype. EHEC-Hly breakdown occurred as a multistage process with the formation of characteristic fragments with relative molecular masses of ∼82 kDa and/or ∼84 kDa and ∼34 kDa. The initial cleavage occurred in the N-terminal hydrophobic domain of EHEC-Hly between Leu235 and Ser236 and abolished its haemolytic activity. In a cellular infection system, the cytolytic potential of EHEC-Hly-secreting recombinant strains was abolished when EspPα was coexpressed. EHEC in contact with human intestinal epithelial cells simultaneously upregulated their EHEC-Hly and EspP indicating that both molecules might interact under physiological conditions. We propose the concept of bacterial effector molecule interference (BEMI), reflecting the concerted interplay of virulence factors. Interference between effector molecules might be an additional way to regulate virulence functions and increases the complexity of monomolecular phenotypes.

[1]  K. Sandvig,et al.  Shiga toxins. , 2012, Toxicon : official journal of the International Society on Toxinology.

[2]  B. Finlay,et al.  Bacterial Macroscopic Rope-like Fibers with Cytopathic and Adhesive Properties* , 2010, The Journal of Biological Chemistry.

[3]  B. Sarg,et al.  EspP, a Serine Protease of Enterohemorrhagic Escherichia coli, Impairs Complement Activation by Cleaving Complement Factors C3/C3b and C5 , 2010, Infection and Immunity.

[4]  J. Besser,et al.  Characteristics of O157 versus non-O157 Shiga toxin-producing Escherichia coli infections in Minnesota, 2000-2006. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  H. Karch,et al.  Structure and Function Relationship of the Autotransport and Proteolytic Activity of EspP from Shiga Toxin-Producing Escherichia coli , 2009, PloS one.

[6]  M. Dierich,et al.  Serine protease espP subtype alpha, but not beta or gamma, of Shiga toxin-producing Escherichia coli is associated with highly pathogenic serogroups. , 2009, International journal of medical microbiology : IJMM.

[7]  H. Karch,et al.  Vesicular stabilization and activity augmentation of enterohaemorrhagic Escherichia coli haemolysin , 2009, Molecular microbiology.

[8]  A. Friedrich,et al.  Shiga toxins, glycosphingolipid diversity, and endothelial cell injury , 2009, Thrombosis and Haemostasis.

[9]  A. Mellmann,et al.  Analysis of Collection of Hemolytic Uremic Syndrome–associated Enterohemorrhagic Escherichia coli , 2008, Emerging infectious diseases.

[10]  J. Paton,et al.  Clathrin‐dependent trafficking of subtilase cytotoxin, a novel AB5 toxin that targets the endoplasmic reticulum chaperone BiP , 2008, Cellular microbiology.

[11]  R. Cherla,et al.  Shiga toxin 1 induces apoptosis through the endoplasmic reticulum stress response in human monocytic cells , 2008, Cellular microbiology.

[12]  A. Mellmann,et al.  Shiga Toxin-Mediated Hemolytic Uremic Syndrome: Time to Change the Diagnostic Paradigm? , 2007, PloS one.

[13]  A. Mellmann,et al.  Subtypes of the Plasmid-Encoded Serine Protease EspP in Shiga Toxin-Producing Escherichia coli: Distribution, Secretion, and Proteolytic Activity , 2007, Applied and Environmental Microbiology.

[14]  A. Friedrich,et al.  Hemolysin from Shiga toxin-negative Escherichia coli O26 strains injures microvascular endothelium. , 2007, Microbes and infection.

[15]  C. Gyles.  Shiga toxin-producing Escherichia coli: an overview. , 2007, Journal of animal science.

[16]  A. Mellmann,et al.  Structural and functional differences between disease-associated genes of enterohaemorrhagic Escherichia coli O111. , 2007, International journal of medical microbiology : IJMM.

[17]  C. Sears,et al.  The emerging clinical importance of non-O157 Shiga toxin-producing Escherichia coli. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  G. Frankel,et al.  Comparison of colonization dynamics and pathology of mice infected with enteropathogenic Escherichia coli, enterohaemorrhagic E. coli and Citrobacter rodentium. , 2006, FEMS microbiology letters.

[19]  A. Friedrich,et al.  Shiga toxin activatable by intestinal mucus in Escherichia coli isolated from humans: predictor for a severe clinical outcome. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  J. Wells,et al.  Non-O157 Shiga toxin-producing Escherichia coli infections in the United States, 1983-2002. , 2005, The Journal of infectious diseases.

[21]  H. Karch,et al.  Enterohaemorrhagic Escherichia coli in human medicine. , 2005, International journal of medical microbiology : IJMM.

[22]  V. Wendisch,et al.  Regulation of type 1 fimbriae synthesis and biofilm formation by the transcriptional regulator LrhA of Escherichia coli. , 2005, Microbiology.

[23]  H. Karch,et al.  Consequences of enterohaemorrhagic Escherichia coli infection for the vascular endothelium , 2005, Thrombosis and Haemostasis.

[24]  P. Tarr,et al.  Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome , 2005, The Lancet.

[25]  H. Karch,et al.  Cytolethal Distending Toxin from Shiga Toxin-Producing Escherichia coli O157 Causes Irreversible G2/M Arrest, Inhibition of Proliferation, and Death of Human Endothelial Cells , 2005, Infection and Immunity.

[26]  P. Srimanote,et al.  A New Family of Potent AB5 Cytotoxins Produced by Shiga Toxigenic Escherichia coli , 2004, The Journal of experimental medicine.

[27]  J. Peter-Katalinic,et al.  Mistletoe lectin I is a sialic acid-specific lectin with strict preference to gangliosides and glycoproteins with terminal Neu5Ac alpha 2-6Gal beta 1-4GlcNAc residues. , 2004, Biochemistry.

[28]  H. Karch,et al.  Phenotypic and Genotypic Analyses of Enterohemorrhagic Escherichia coli O145 Strains from Patients in Germany , 2004, Journal of Clinical Microbiology.

[29]  Gtacggactaacagggaactg,et al.  A New Family of Potent AB 5 Cytotoxins Produced by Shiga Toxigenic Escherichia coli , 2004 .

[30]  Gilbert S Chen,et al.  Shiga toxin-producing Escherichia coli in Montana: bacterial genotypes and clinical profiles. , 2003, The Journal of infectious diseases.

[31]  A. Edefonti,et al.  Shiga Toxin–Producing Escherichia coli Infections Associated with Hemolytic Uremic Syndrome, Italy, 1988–2000 , 2003, Emerging infectious diseases.

[32]  J. Nataro,et al.  Functional Comparison of Serine Protease Autotransporters of Enterobacteriaceae , 2002, Infection and Immunity.

[33]  A. O’Brien,et al.  Activation of Shiga toxin type 2d (Stx2d) by elastase involves cleavage of the C‐terminal two amino acids of the A2 peptide in the context of the appropriate B pentamer , 2002, Molecular microbiology.

[34]  D. Acheson,et al.  Shiga Toxin Translocation across Intestinal Epithelial Cells Is Enhanced by Neutrophil Transmigration , 2001, Infection and Immunity.

[35]  J. H. Green,et al.  The United States National Prospective Hemolytic Uremic Syndrome Study: microbiologic, serologic, clinical, and epidemiologic findings. , 2001, The Journal of infectious diseases.

[36]  I. Henderson,et al.  Virulence Functions of Autotransporter Proteins , 2001, Infection and Immunity.

[37]  R. Welch,et al.  RTX toxin structure and function: a story of numerous anomalies and few analogies in toxin biology. , 2001, Current topics in microbiology and immunology.

[38]  F. Gilles,et al.  Selective expression of adhesion molecules on human brain microvascular endothelial cells , 1997, Journal of Neuroimmunology.

[39]  H. Karch,et al.  EspP, a novel extracellular serine protease of enterohaemorrhagic Escherichia coli O157:H7 cleaves human coagulation factor V , 1997, Molecular microbiology.

[40]  T. Honda,et al.  In vitro proteolytic processing and activation of the recombinant precursor of El Tor cytolysin/hemolysin (pro-HlyA) of Vibrio cholerae by soluble hemagglutinin/protease of V. cholerae, trypsin, and other proteases , 1996, Infection and immunity.

[41]  R. Benz,et al.  Pore-forming properties of the plasmid-encoded hemolysin of enterohemorrhagic Escherichia coli O157:H7. , 1996, European journal of biochemistry.

[42]  A. Shevchenko,et al.  Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. , 1996, Analytical chemistry.

[43]  R. Welch,et al.  Characterization of an RTX toxin from enterohemorrhagic Escherichia coli O157:H7 , 1996, Infection and immunity.

[44]  K. Sandvig,et al.  Furin-induced Cleavage and Activation of Shiga Toxin (*) , 1995, The Journal of Biological Chemistry.

[45]  L. Beutin,et al.  Molecular analysis of the plasmid-encoded hemolysin of Escherichia coli O157:H7 strain EDL 933 , 1995, Infection and immunity.

[46]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.